Hypercholesterolemia Clinical Trial
Official title:
Independent Effects of High-cholesterol (High-egg) and High-saturated Fat Diets on LDL-cholesterol
NCT number | NCT05267522 |
Other study ID # | 204327 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | March 1, 2022 |
Est. completion date | August 31, 2023 |
Verified date | March 2022 |
Source | University of South Australia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will comprise a randomized controlled, counter-balanced, cross-over trial to evaluate the independent effects of a high cholesterol (high egg), low saturated fat diet and a high saturated fat, low cholesterol diet on blood lipids. Evaluations also include analysis of physical activity as there is emerging evidence that the lutein and zeaxanthin in egg yolk may increase physical activity levels by crossing the blood-brain barrier and altering neuronal function. The study will also investigate effects on a number of novel lipoprotein parameters (particle size and particle concentrations).
Status | Completed |
Enrollment | 77 |
Est. completion date | August 31, 2023 |
Est. primary completion date | August 10, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - Male or female, aged 18 - 60 years - Blood LDL-C <3.5 mmol/L (measured at screening using an automated analyser (Cholestech LDX System). - Non-smoker (or other nicotine products) (minimum 6 months). Exclusion Criteria: - Have diagnosed cardiovascular disease (including uncontrolled high blood pressure) or a chronic disease, including Type-1 or -2 diabetes, kidney or liver disease, gastrointestinal disorders requiring medical nutrition therapy (e.g., Crohn's disease, irritable bowel, coeliac disease) or any other condition that may have an impact on study outcomes. - Have allergies or strong aversion to eggs or other components of the test foods (diets are not suitable for vegetarians). - Consume more than 5 eggs per week in the month prior to beginning the trial. - Participant has a recent history (within 12 months) or strong potential for alcohol abuse. Defined as >14 standard drinks per week. - Have changed medication or supplementation that might affect study outcomes in the last 3 months. - Take vitamin, mineral, herbal supplementation, or medications that may have an impact on study outcomes. - Are already involved in another research project within 30 days of commencement of the present study that in the opinion of the investigators will be unsuitable for this study. - Are pregnant or breastfeeding. - Show unwillingness to be randomized to either experimental group. - Failure to satisfy the investigator regarding suitability to participate for any other reason. - Are unwilling or unable to provide written informed consent. |
Country | Name | City | State |
---|---|---|---|
Australia | University of South Australia Clinical Trial Facility | Adelaide | South Australia |
Lead Sponsor | Collaborator |
---|---|
University of South Australia | American Egg Board |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Low-density lipoprotein cholesterol (LDL-C) | Plasma LDL-C levels (mmol/L) | Baseline | |
Primary | Low-density lipoprotein cholesterol (LDL-C) | Plasma LDL-C levels (mmol/L) | 5 weeks | |
Primary | Low-density lipoprotein cholesterol (LDL-C) | Plasma LDL-C levels (mmol/L) | 10 weeks | |
Primary | Low-density lipoprotein cholesterol (LDL-C) | Plasma LDL-C levels (mmol/L) | 15 weeks | |
Secondary | Blood lipid profiling | Plasma lipid, lipoprotein subclasses, cholesterol, and apolipoproteins | Baseline | |
Secondary | Blood lipid profiling | Plasma lipid, lipoprotein subclasses, cholesterol, and apolipoproteins | 5 weeks | |
Secondary | Blood lipid profiling | Plasma lipid, lipoprotein subclasses, cholesterol, and apolipoproteins | 10 weeks | |
Secondary | Blood lipid profiling | Plasma lipid, lipoprotein subclasses, cholesterol, and apolipoproteins | 15 weeks | |
Secondary | Fasting glucose | Plasma glucose levels (mmol/L) | Baseline | |
Secondary | Fasting glucose | Plasma glucose levels (mmol/L) | 5 weeks | |
Secondary | Fasting glucose | Plasma glucose levels (mmol/L) | 10 weeks | |
Secondary | Fasting glucose | Plasma glucose levels (mmol/L) | 15 weeks | |
Secondary | Physical activity levels | Amount of time (min) spent sedentary and engaged in light or moderate-vigorous physical activity | Baseline | |
Secondary | Physical activity levels | Amount of time (min) spent sedentary and engaged in light or moderate-vigorous physical activity | 5 weeks | |
Secondary | Physical activity levels | Amount of time (min) spent sedentary and engaged in light or moderate-vigorous physical activity | 10 weeks | |
Secondary | Physical activity levels | Amount of time (min) spent sedentary and engaged in light or moderate-vigorous physical activity | 15 weeks | |
Secondary | Waist circumference | Waist circumference (cm) measured at the midpoint between the lower costal (10th rib) border and the iliac crest. | Baseline | |
Secondary | Waist circumference | Waist circumference (cm) measured at the midpoint between the lower costal (10th rib) border and the iliac crest. | 5 weeks | |
Secondary | Waist circumference | Waist circumference (cm) measured at the midpoint between the lower costal (10th rib) border and the iliac crest. | 10 weeks | |
Secondary | Waist circumference | Waist circumference (cm) measured at the midpoint between the lower costal (10th rib) border and the iliac crest. | 15 weeks | |
Secondary | Blood Pressure | Seated blood pressure (mmHg) | Baseline | |
Secondary | Blood Pressure | Seated blood pressure (mmHg) | 5 weeks | |
Secondary | Blood Pressure | Seated blood pressure (mmHg) | 10 weeks | |
Secondary | Blood Pressure | Seated blood pressure (mmHg) | 15 weeks | |
Secondary | Dietary saturated fat intake | Analysis of dietary intake based on 5-day food diaries | Baseline | |
Secondary | Dietary saturated fat intake | Analysis of dietary intake based on 5-day food diaries | 5 weeks | |
Secondary | Dietary saturated fat intake | Analysis of dietary intake based on 5-day food diaries | 10 weeks | |
Secondary | Dietary saturated fat intake | Analysis of dietary intake based on 5-day food diaries | 15 weeks | |
Secondary | Dietary cholesterol intake | Analysis of dietary intake based on 5-day food diaries | Baseline | |
Secondary | Dietary cholesterol intake | Analysis of dietary intake based on 5-day food diaries | 5 weeks | |
Secondary | Dietary cholesterol intake | Analysis of dietary intake based on 5-day food diaries | 10 weeks | |
Secondary | Dietary cholesterol intake | Analysis of dietary intake based on 5-day food diaries | 15 weeks | |
Secondary | Dietary Energy intake | Analysis of dietary intake based on 5-day food diaries | Baseline | |
Secondary | Dietary Energy intake | Analysis of dietary intake based on 5-day food diaries | 5 weeks | |
Secondary | Dietary Energy intake | Analysis of dietary intake based on 5-day food diaries | 10 weeks | |
Secondary | Dietary Energy intake | Analysis of dietary intake based on 5-day food diaries | 15 weeks | |
Secondary | Dietary Macronutrients | Analysis of dietary intake based on food diaries | Baseline | |
Secondary | Dietary Macronutrients | Analysis of dietary intake based on food diaries | 5 weeks | |
Secondary | Dietary Macronutrients | Analysis of dietary intake based on food diaries | 10 weeks | |
Secondary | Dietary Macronutrients | Analysis of dietary intake based on food diaries | 15 weeks | |
Secondary | Dietary Lutein+Zeaxanthin | Analysis of dietary intake based on food diaries | Baseline | |
Secondary | Dietary Lutein+Zeaxanthin | Analysis of dietary intake based on food diaries | 5 weeks | |
Secondary | Dietary Lutein+Zeaxanthin | Analysis of dietary intake based on food diaries | 10 weeks | |
Secondary | Dietary Lutein+Zeaxanthin | Analysis of dietary intake based on food diaries | 15 weeks | |
Secondary | Sleep | Sleep patterns assessed using accelerometers | Baseline | |
Secondary | Sleep | Sleep patterns assessed using accelerometers | 5 weeks | |
Secondary | Sleep | Sleep patterns assessed using accelerometers | 10 weeks | |
Secondary | Sleep | Sleep patterns assessed using accelerometers | 15 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Recruiting |
NCT03947866 -
Ezetimibe-Rosuvastatin Evaluation Study
|
||
Completed |
NCT01709513 -
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
|
Phase 3 | |
Completed |
NCT01212900 -
Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression
|
Phase 4 | |
Completed |
NCT00001154 -
Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
|
||
Completed |
NCT02550288 -
A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)
|
Phase 3 | |
Completed |
NCT03929198 -
Translation of Pritikin Program to the Community
|
N/A | |
Completed |
NCT04485793 -
Effect of a Dietary Supplement on Lipid Pattern and Liver Parameters in Hypercholesterolemia
|
N/A | |
Completed |
NCT02341924 -
Validating the "Foods for Health" Portfolio of Functional Food Products
|
N/A | |
Active, not recruiting |
NCT02223793 -
Vascular Lifestyle-Intervention and Screening in Pharmacy
|
N/A | |
Completed |
NCT01941836 -
Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients
|
Phase 2 | |
Completed |
NCT01934608 -
The Effect of Synching Prescription Refills on Adherence
|
N/A | |
Recruiting |
NCT01705873 -
Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen
|
N/A | |
Completed |
NCT01670734 -
Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01678521 -
Effect of LDL-apheresis on PTX3 Plasma Levels in Hypercholesterolemic Patients
|
N/A | |
Completed |
NCT01370590 -
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1)
|
Phase 3 | |
Completed |
NCT01370603 -
A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/40 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 40 mg Tablets in Participants With High Cholesterol (MK-0653C-190 AM1)
|
Phase 3 | |
Completed |
NCT01768403 -
Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia
|
N/A | |
Completed |
NCT01446679 -
Special Drug Use-Results Survey of Lipitor Tablets
|
N/A | |
Completed |
NCT01575171 -
Using Nudges to Implement Comparative Effectiveness
|
N/A |